Skip to main content
KERYXinactive

KERYX BIOPHARMACEUTICALS INC

Biopharma developer (SEC filing verified)·Commercial·CEO: Jodie P. Morrison Interim
HematologyNephrology

KERYX evidence brief

What we can confirm

BioSniper Score:
6.7 / 10
Lead Asset:
auryxia (Approved)

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

BioSniper Score: 6.7 / 10 · Lead Asset: auryxia (Approved)
BioSniper AIPage evidence connected

Prepared research question

What matters most for KERYX—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

6.7/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

auryxia (Approved)

Next Catalyst

—

Tracking 1 pipeline candidate · 2 clinical trials · 1 FDA decision for KERYX BIOPHARMACEUTICALS INC.

Run KERYX BIOPHARMACEUTICALS INC through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available KERYX BIOPHARMACEUTICALS INC facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

Cash RunwayN/A

Cash runway data unavailable

Financial HealthN/A

Financial health data unavailable

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company

Regulatory

Run my thesis on this company

Governance

Run my thesis on this company

Frequently asked questions

What is KERYX BIOPHARMACEUTICALS INC's lead drug candidate?

KERYX BIOPHARMACEUTICALS INC's most advanced tracked candidate is auryxia (Approved) for Treatment of iron deficiency anemia in adults with CKD, not on dialysis.

Who is the CEO of KERYX BIOPHARMACEUTICALS INC?

Jodie P. Morrison Interim is the chief executive officer of KERYX BIOPHARMACEUTICALS INC (KERYX).

What therapeutic areas does KERYX BIOPHARMACEUTICALS INC focus on?

KERYX BIOPHARMACEUTICALS INC develops therapies across Hematology, Nephrology.

923 companies304,846 SEC filings22,651 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.